A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria responsive to antibiotics once again.
Jørn Bolstad and his chemist colleagues hope that the substance will soon be able to tackle the tremendous problems associated with multidrug resistant tuberculosis (MDR-TB). But first, they need to find investors interested in getting the substance onto the market.
Before the development of penicillin, people dropped like flies in response to minor infections: in the lungs, in small cuts. Even pimples could grow to boils that killed. But one of the main killers prior to the discovery of antibiotics was tuberculosis.
The deadly infectious disease that typically affects the lungs has returned. It has developed a resistance to the majority of antibiotics that would otherwise kill the tuberculosis bacteria. Currently, the disease does not pose an imminent threat to Denmark or the West. However, resistant strains of the bacteria are nearing the region’s borders. This is one of the reasons why doctors around the world are busy trying to solve the problem of drug resistance.
The bacteria shed killing substances
While those bacteria that have developed a resistance remain vulnerable to antibiotics, they have developed an ability to shed bacteria killing substances before any damage is done to them. Colloquially, this is referred to as pooping the substance out, but the scientific formulation is that these bacteria activate an efflux pump.
Jørn Bolstad Christensen has isolated a substance able to block the efflux pump so that an antibiotic remains in bacteria until the bacteria dies.
You could say that we cure bacteria of their resistance, and slay them with antibiotics, explains Associate Professor Jørn Bolstad Christensen.
From antipsychotic to killing bacteria
Working with doctors Jette Kristiansen from the University of Southern Denmark and Oliver Hendricks from the King Christian X’s Hospital for Rheumatic Diseases in Gråsten, Denmark, Jørn Bolstad Christensen discovered that Thioridazin, an antipsychotic drug, was able to kill bacteria without any noticeably harmful effects upon humans. Still, the chemists had an idea that could make the substance more benign.
We now have a substance that is able to block the bacteria’s efflux pump. At very most, recipients of the medication may become slightly sluggish. This is also because very small doses are needed to affect the bacteria, says Jørn Bolstad Christensen.
Researchers hope for quick approval
Because Thioridazin is an approved drug, the research team hopes that the new anti-resistance medication, JEK 47, will be approved without going through the entire process that new pharmaceuticals are typically subjected to. If this is the case, JEK 47 will most likely be a cheap medication that a pharmaceuticals manufacturer could release quickly. However if an investor does not show interest, Christensen is certain about his next step.
The Latest on: Antibiotic resistance
[google_news title=”” keyword=”Antibiotic resistance” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antibiotic resistance
- 'Just in case' antibiotics widely overused during COVID-19, says UN health agencyon April 26, 2024 at 10:56 pm
Antibiotics saw 'extensive overuse' globally among hospitalised COVID-19 patients during the pandemic without improving clinical outcomes, while also potentially increasing the already serious and ...
- Dr. James Gill's insights on combating the global crisis of antimicrobial resistanceon April 26, 2024 at 10:42 pm
Dr. James Gill, a Clinical Lecturer at the University of Warwick and a practicing GP, will attend a pivotal event hosted at the House of Lords on Monday (April 29) focused on combating the global ...
- AI Model Shows Promise in Fighting Drug Resistanceon April 26, 2024 at 8:31 pm
As antibiotic resistance continues to pose a formidable challenge, AI-driven solutions offer a beacon of hope in the fight against drug-resistant pathogens.
- Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Miceon April 26, 2024 at 4:03 pm
Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi. Although only tested in mice, the ...
- Experts develop way to harness CRISPR technology to deal with antimicrobial resistanceon April 26, 2024 at 3:10 pm
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be ...
- Common antibiotic Neosporin may shield against viral respiratory infectionson April 26, 2024 at 9:00 am
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- Study: Antibiotic use in moderate COVID-19 linked to clinical deteriorationon April 26, 2024 at 7:56 am
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
- What to Know About Pivya, the New Antibiotic Treatment for UTIson April 26, 2024 at 4:06 am
The Food and Drug Administration recently approved Pivya (pivmecillinam) to treat uncomplicated UTIs in female adults. Clinical trials show that Pivya is effective and side effects are limited.
- A Vaccine to Fight Antibiotic Resistanceon April 25, 2024 at 2:25 pm
MSU, Harvard Medical School team up to expand vaccine science’s role in the fight against MRSA and other infections ...
- Climate change fuels the rise of global antimicrobial resistanceon April 25, 2024 at 10:34 am
Climate change exacerbates antimicrobial resistance by altering environments where microbes thrive, leading to increased disease spread.
via Bing News